J. Tamaoki et al., Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways, AM J P-LUNG, 20(2), 1999, pp. L351-L357
Citations number
37
Categorie Soggetti
da verificare
Journal title
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
To determine the effect of the antiallergic drug azelastine on airway mucos
al inflammation, we studied airway microvascular permeability in response t
o platelet-activating factor (PAF) in pathogen-free rats. Vascular permeabi
lity and neutrophil accumulation were assessed by the percent area occupied
by Monastral blue-labeled blood vessels and by myeloperoxidase-containing
granulocytes, respectively, in whole mounts of the trachea and main bronchu
s. Intravenous PAF caused dose-dependent increases in the area density of M
onastral blue-labeled vessels and neutrophil influx, and the former effect
was inhibited by depletion of circulating neutrophils by cyclophosphamide o
r treatment with the neutrophil elastase inhibitor ONO-5046. Pretreatment w
ith azelastine inhibited PAF-induced vascular leakage without affecting neu
trophil accumulation. This inhibitory effect of azelastine was not seen in
neutropenic rats and ONO-5046-treated rats. PAF increased neutrophil elasta
se contents in bronchoalveolar lavage fluid, an effect that was inhibited b
y azelastine. Therefore, azelastine attenuates PAF-induced airway mucosal m
icrovascular leakage, probably involving inhibition of the release of neutr
ophil elastase from activated neutrophils.